Traders should monitor for potential downward pressure on the stock, especially if no offsetting positive news emerges. The concentration of sales among top executives suggests a lack of confidence in near-term upside or an effort to diversify after a run-up. Consider this a warning sign ahead of earnings or clinical updates.
TARS drugs
TARS drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 16 $68.90entry
- T+1 · 8mo ago +1.29%α +1.02% · $69.79
- T+5 · 8mo ago −6.92%α −4.88% · $64.13
- T+20 · 7mo ago +7.13%α +3.35% · $73.81
- T+60 · 5mo ago −13.44%α −23.92% · $59.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven executives at Tarsus Pharmaceuticals, including the CEO, COO, and CMO, sold shares in a coordinated open-market cluster over three days, realizing $2.6 million in total proceeds. The sales occurred at prices between $66.75 and $68.71, with the largest individual transaction coming from the CEO, who sold over $1.6 million worth of stock. This represents a material insider selling event involving key leadership.
Key Financial Metrics
Key Facts
- CEO Bobak Azamian sold $1.6 million in shares over two days (11,964 shares at $67 and 11,667 at $68.71).
- All seven insiders involved were C-suite executives, including COO, CCO, CMO, GC, CHRO, and CEO.
- Total cluster value: $2.6 million in open-market sales over 7 days.
- Average sale price: ~$67.50 per share, near recent highs.
- Total value represents ~0.1% of TARS's $2.7B market cap, significant for insider activity.
Financial Impact
$2.6 million in insider sales over 7 days, primarily by C-suite executives
Risk Factors
- Perceived insider pessimism could erode investor confidence.
- Further selling by other insiders may follow.
- Stock may face headwinds if no fundamental catalysts emerge to justify valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (15 trades, 7d window) | cluster-TARS-1774386373155 |
Track record
21 reports on TARS
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers